Novartis has entered a worldwide licensing and partnership agreement with PTC Therapeutics to develop PTC518, a potential oral therapy for Huntington's disease (HD). The PTC518 Huntington's ...

About Aquestive Therapeutics, Inc.Aq Reports positive ... bring meaningful improvement to patients' lives through innovative science and delivery technologies, today The headline numbers for ...

Maze Therapeutics, a kidney disease therapy developer ... MAZE is doing interesting science and I would be interested in seeing how it does in the coming years. I do not like to invest in IPOs ...

A team of researchers led by Dr. KIM V. Narry, director of the Center for RNA Research at the Institute for Basic Science (IBS), has uncovered a key cellular mechanism that affects the function of ...